Difference between revisions of "Semuloparin (AVE-5026)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Warner-admin moved page Semuloparin (AVE5026) to Semuloparin (AVE-5026) without leaving a redirect) |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin. | + | Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.<ref name="SAVE-ONCO"> Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. [https://doi.org/10.1056/NEJMoa1108898 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22335737/ PubMed]</ref> |
Route: SC | Route: SC | ||
Latest revision as of 23:14, 2 September 2023
General information
Class/mechanism: Hemisynthetic ultra low molecular weight heparin (ULMWH), binds to antithrombin III, accelerating its activity and inhibiting factor Xa, factor IIa, and thrombin.[1]
Route: SC
Extravasation: n/a
Patient drug information
No information available.
Also known as
- Code name: AVE-5026
References
- ↑ Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9. link to original article PubMed